Traditional approaches to bringing cell therapies to market have many challenges — from high-risk development and unpredictable manufacturing processes to unreliable income models. Alder Therapeutics have developed AlderEdge, a unique drug development philosophy that de-risks the development of cell therapies. By keeping the commercial product in mind from the start, the AlderEdge approach de-risks development, helping to bring advanced cell therapies to market, faster, and more reliably.
Alder Therapeutics joined NOME in 2024.